Diabetes Research and Clinical Practice
Volume 74, Issue 2, Supplement , Pages S63-S69 , 30 November 2006

Therapy targeting β-cell survival and function in type 2 diabetes mellitus

References 

  1. Narayan KMV, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290:1884–1890
  2. Matthews DR. The natural history of diabetes-related complications: the UKPDS experience. United Kingdom Prospective Diabetes Study. Diab. Obes. Metab. 1999;1:S7–S13
  3. Beck-Nielsen H, Vaag A, Poulsen P, Gaster M. Metabolic and genetic influence on glucose metabolism in type 2 diabetic subjects—experiences from relatives and twin studies. Best Practice Res. Clin. Endocrinol. Metab. 2003;17:445–467
  4. Mills GW, Avery PJ, McCarthy MI, Hattersley AT, Levy JC, Hitman GA, et al. Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to Type 2 diabetes. Diabetologia. 2004;47:732–738
  5. Permutt MA, Wasson J, Cox N. Genetic epidemiology of diabetes. J. Clin. Invest. 2005;115:1431–1439
  6. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of Type 2 diabetes development. Diabetes Care. 2001;24:89–94
  7. Nyholm B, Porksen N, Juhl CB, Gravholt CH, Butler PC, Weeke J, et al. Assessment of insulin secretion in relatives of patients with type 2 (non-insulin-dependent) diabetes mellitus: evidence of early beta-cell dysfunction. Metabolism. 2000;49:896–905
  8. Neel JV. Diabetes mellitus a “thrifty” genotype rendered detrimental by progress. Am. J. Hum. Genet. 1962;14:352–353
  9. Stefan N, Weyer C, Levy-Marchal C, Stumvoll M, Knowler WC, Tataranni PA, et al. Endogenous glucose production, insulin sensitivity, and insulin secretion in normal glucose-tolerant Pima Indians with low birth weight. Metabolism. 2004;53:904–911
  10. Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, Nissen M, et al. Predictors of longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes. 2005;54:166–174
  11. Barroso I. Genetics of Type 2 diabetes. Diab. Med. 2005;22:517–535
  12. UK prospective diabetes study 16, Overview of 6 years’ therapy of type II diabetes: a progressive disease, Diabetes 44 (1995) 1249–1258.
  13. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Invest. 1999;104:787–794
  14. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J. Clin. Invest. 1984;74:1318–1328
  15. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–110
  16. Vilsboll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1. Diabetes Care. 2000;23:807–812
  17. Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 2005;90:5991–5997
  18. Song SH, Rhodes CJ, Veldhuis JD, Butler PC. Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets. Endocrinology. 2003;144:3399–3405
  19. Laedtke T, Kjems L, Porksen N, Schmitz O, Veldhuis J, Kao PC, et al. Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am. J. Physiol. 2000;279:E520–E528
  20. Hollingdal M, Juhl CB, Dall R, Sturis J, Veldhuis JD, Schmitz O, et al. Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. Diabetologia. 2002;45:49–55
  21. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24:89–94
  22. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J. Clin. Endocrinol. Metab. 2005;90:493–500
  23. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 1988;318:1231–1239
  24. Sturis J, Polonsky KS, Shapiro ET, Blackman JD, O’Meara NM, Van Cauter E. Abnormalities in the ultradian oscillations of insulin secretion and glucose levels in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1992;35:681–689
  25. O’Rahilly S, Turner RC, Matthews DR. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N. Engl. J. Med. 1988;318:1225–1230
  26. Calles-Escandon J, Robbins DC. Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes. 1987;36:1167–1172
  27. Polonsky KS, Sturis J, Van Cauter E. Temporal profiles and clinical significance of pulsatile insulin secretion. Horm. Res. 1998;49:178–184
  28. Nielsen LL. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov. Today. 2005;10:703–710
  29. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 2003;88:3082–3089
  30. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia. 2000;43:278–284
  31. Sturis J, Scheen AJ, Leproult R, Polonsky KS, Van Cauter E. 24-hour glucose profiles during continuous or oscillatory insulin infusion. Demonstration of the functional significance of ultradian insulin oscillations. J. Clin. Invest. 1995;95:1464–1471
  32. Matthews DR. Oscillatory insulin secretion: a variable phenotypic marker. Diab. Med. 1996;13:S53–S58
  33. Juhl CB, Sturis J, Hollingdal M, Schmitz O. Acute insulin responses to intravenous glucose and GLP-1 are independent of preceding high-frequency insulin pulse-defects induced by glucose entrainment in healthy humans. Horm. Metab. Res. 2005;37:40–44
  34. Larsen MO, Juhl CB, Porksen N, Gotfredsen CF, Carr RD, Ribel U, et al. Beta-cell function and islet morphology in normal, obese, and obese beta-cell mass-reduced Gottingen minipigs. Am. J. Physiol. 2005;288:E412–E421
  35. Sturis J, Pugh WL, Tang J, Polonsky KS. Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF rat. Am. J. Physiol. 1995;269:E786–E792
  36. Juhl CB, Hollingdal M, Porksen N, Prange A, Lonnqvist F, Schmitz O. Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J. Clin. Endocrinol. Metab. 2003;88:3794–3800
  37. Juhl CB, Porksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes. Diabetes. 2001;50:1778–1784
  38. Hollingdal M, Sturis J, Gall MA, Damsbo P, Pincus S, Veldhuis JD, et al. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes. Diab. Med. 2005;22:1408–1413
  39. Juhl CB, Schmitz O, Pincus S, Holst JJ, Veldhuis J, Porksen N. Short-term treatment with GLP-1 increases pulsatile insulin secretion in Type II diabetes with no effect on orderliness. Diabetologia. 2000;43:583–588
  40. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002;51:424–429
  41. Kashima Y, Miki T, Shibasaki T, Ozaki N, Miyazaki M, Yano H, et al. Critical role of cAMP-GEFII--Rim2 complex in incretin-potentiated insulin secretion. J. Biol. Chem. 2001;276:46046–46053
  42. Matschinsky FM. Glucokinase, glucose homeostasis, and diabetes mellitus. Curr. Diab. Rep. 2005;5:171–176
  43. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes. 2004;53:2397–2403
  44. Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC. Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes. 2004;53:1509–1516
  45. Kendall DM, Sutherland DE, Najarian JS, Goetz FC, Robertson RP. Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. N. Engl. J. Med. 1990;322:898–903
  46. Larsen MO, Rolin B, Sturis J, Wilken M, Carr RD, Porksen N, et al. Measures of insulin responses as predictive markers of pancreatic beta-cell mass in normal and beta-cell reduced lean and obese Gottingen minipigs in vivo. Am. J. Physiol. 2005;
  47. Van Tine BA, Patterson AJ, Kudlow JE. Assignment of N-acetyl-d-glucosaminidase (Mgea5) to rat chromosome 1q5 by tyramide fluorescence in situ hybridization (T-FISH): synteny between rat, mouse and human with insulin degradation enzyme (IDE). Cytogenet. Genome Res. 2003;103:202B
  48. Koh EH, Kim MS, Park JY, Kim HS, Youn JY, Park HS, et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes. 2003;52:2331–2337
  49. Joseph JW, Koshkin V, Saleh MC, Sivitz WI, Zhang CY, Lowell BB, et al. Free fatty acid-induced beta-cell defects are dependent on uncoupling protein 2 expression. J. Biol. Chem. 2004;279:51049–51056
  50. Chan CB, De Leo D, Joseph JW, McQuaid TS, Ha XF, Xu F, et al. Increased uncoupling protein-2 levels in beta-cells are associated with impaired glucose-stimulated insulin secretion: mechanism of action. Diabetes. 2001;50:1302–1310
  51. Liu G, Rondinone CM. JNK: bridging the insulin signaling and inflammatory pathway. Curr. Opin. Invest. Drugs. 2005;6:979–987
  52. Yang Z, Chen M, Ellett JD, Carter JD, Brayman KL, Nadler JL. Inflammatory blockade improves human pancreatic islet function and viability. Am. J. Transplant. 2005;5:475–483
  53. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J. Mol. Med. 2003;81:455–470
  54. Bregenholt S, Moldrup A, Blume N, Karlsen AE, Nissen FB, Tornhave D, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem. Biophys. Res. Commun. 2005;330:577–584
  55. Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm. Metab. Res. 2004;36:804–810
  56. Stoffers DA, Desai BM, DeLeon DD, Simmons RA. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes. 2003;52:734–740
  57. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes. 2002;51:1443–1452
  58. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes. 2001;50:1562–1570
  59. Tan MH, Baksi A, Krahulec B, Kubalski P, Stankiewicz A, Urquhart R, et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care. 2005;28:544–550

PII: S0168-8227(06)00283-X

doi: 10.1016/j.diabres.2006.06.014

Diabetes Research and Clinical Practice
Volume 74, Issue 2, Supplement , Pages S63-S69 , 30 November 2006

Article Tools

* Image Usage & Resolution